Hot search: Textile  china,  business  consumer  hannover  report  financial  economy  from  five-year 
 
Home > News > Market > Content

Immunovaccine Has Reported a Net Loss of $1.7m for The Third Quarter

increase font size  reduce font Add date: 2016-11-30  Hits:40
Core prompt: Immunovaccine has reported a net loss of $1.7m for the third quarter ended 30 September 2012 compared to a net loss of $1.5m for the same quarter in 2011. According to the company the increased

Immunovaccine has reported a net loss of $1.7m for the third quarter ended 30 September 2012 compared to a net loss of $1.5m for the same quarter in 2011.

According to the company the increased loss is due to the $155,000 increase in general and administration expenses, a $33,000 increase in business development expenses and a $28,000 increase in research and development costs.

Immunovaccine CEO John Trizzino said the success of an effective therapeutic cancer vaccine will be based on a candidate that brings the right target, the right immune enhancement technology and the right therapy to the patient.

"The positive results from our DPX-Survivac Phase I trial validate this strategy by triggering a cancer fighting immune response in these ovarian cancer patients," Trizzino added

"The data reported from our work on a cocaine vaccine and our focus o-n malaria and RSV vaccine candidates along with the expectation that these will be in human clinical trials by 2014, reinforces the value of our DepoVax platform."

 

 
 
[ NewsSearch ]  [ Send Fav ]  [ Share ]  [ Print ]  [ Send Report ]  [ Close ]

 
Total0bar [View All]  Related Comments

 
Photo Recommended
Recommend News
Click Rank
 
Home | Products | Suppliers | News | Tradeshow | Sitemap | Message | RSS Feed